Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 11(1): 4422, 2021 02 24.
Article in English | MEDLINE | ID: mdl-33627688

ABSTRACT

During a first-in-humans clinical trial investigating electron paramagnetic resonance tumor oximetry, a patient injected with the particulate oxygen sensor Printex ink was found to have unexpected fluorodeoxyglucose (FDG) uptake in a dermal nodule via positron emission tomography (PET). This nodule co-localized with the Printex ink injection; biopsy of the area, due to concern for malignancy, revealed findings consistent with ink and an associated inflammatory reaction. Investigations were subsequently performed to assess the impact of oxygen sensors on FDG-PET/CT imaging. A retrospective analysis of three clinical tumor oximetry trials involving two oxygen sensors (charcoal particulates and LiNc-BuO microcrystals) in 22 patients was performed to evaluate FDG imaging characteristics. The impact of clinically used oxygen sensors (carbon black, charcoal particulates, LiNc-BuO microcrystals) on FDG-PET/CT imaging after implantation in rat muscle (n = 12) was investigated. The retrospective review revealed no other patients with FDG avidity associated with particulate sensors. The preclinical investigation found no injected oxygen sensor whose mean standard uptake values differed significantly from sham injections. The risk of a false-positive FDG-PET/CT scan due to oxygen sensors appears low. However, in the right clinical context the potential exists that an associated inflammatory reaction may confound interpretation.

2.
NMR Biomed ; 33(2): e4181, 2020 02.
Article in English | MEDLINE | ID: mdl-31762121

ABSTRACT

Hypoxia is a crucial factor in cancer therapy, determining prognosis and the effectiveness of treatment. Although efforts are being made to develop methods for assessing tumor hypoxia, no markers of hypoxia are currently used in routine clinical practice. Recently, we showed that the combined endogenous MR biomarkers, R1 and R2 *, which are sensitive to [dissolved O2 ] and [dHb], respectively, were able to detect changes in tumor oxygenation induced by a hyperoxic breathing challenge. In this study, we further validated the ability of the combined MR biomarkers to assess the change in tumor oxygenation induced by an allosteric effector of hemoglobin, myo-inositol trispyrophosphate (ITPP), on rat tumor models. ITPP induced an increase in tumor pO2 , as observed using L-band electron paramagnetic resonance oximetry, as well as an increase in both R1 and R2 * MR parameters. The increase in R1 indicated an increase in [O2 ], whereas the increase in R2 * resulted from an increase in O2 release from blood, inducing an increase in [dHb]. The impact of ITPP was then evaluated on factors that can influence tumor oxygenation, including tumor perfusion, saturation rate of hemoglobin, blood pH and oxygen consumption rate (OCR). ITPP decreased blood [HbO2 ] and significantly increased blood acidity, which is also a factor that right-shifts the oxygen dissociation curve. No change in tumor perfusion was observed after ITPP treatment. Interestingly, ITPP decreased OCR in both tumor cell lines. In conclusion, ITPP increased tumor pO2 via a combined mechanism involving a decrease in OCR and an allosteric effect on hemoglobin that was further enhanced by a decrease in blood pH. MR biomarkers could assess the change in tumor oxygenation induced by ITPP. At the intra-tumoral level, a majority of tumor voxels were responsive to ITPP treatment in both of the models studied.


Subject(s)
Biomarkers, Tumor/metabolism , Hemoglobins/metabolism , Magnetic Resonance Spectroscopy , Neoplasms/metabolism , Oxygen/metabolism , Allosteric Regulation , Animals , Cell Line, Tumor , Glioma/diagnostic imaging , Inositol Phosphates/metabolism , Oxygen Consumption , Rats , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/metabolism
3.
MAGMA ; 32(2): 205-212, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30209636

ABSTRACT

OBJECTIVES: Electron paramagnetic resonance (EPR) oximetry using particulate materials allows repeatable measurements of oxygen in tissues. However, the materials identified so far are not medical devices, thus precluding their immediate use in clinical studies. The aim of this study was to assess the magnetic properties of Carbo-Rep®, a charcoal suspension used as a liquid marker for preoperative tumor localization. MATERIALS AND METHODS: Calibration curves (EPR linewidth as a function of pO2) were built using 9-GHz EPR spectrometry. The feasibility of performing oxygen measurements was examined in vivo by using a low-frequency (1 GHz) EPR spectrometer and by inducing ischemia in the gastrocnemius muscle of mice or by submitting rats bearing tumors to different oxygen-breathing challenges. RESULTS: Paramagnetic centers presenting a high oxygen sensitivity were identified in Carbo-Rep®. At 1 GHz, the EPR linewidth varied from 98 to 426 µT in L-band in nitrogen and air, respectively. The sensor allowed repeated measurements of oxygen over 6 months in muscles of mice. Subtle variations of tumor oxygenation were monitored in rats when switching gas breathing from air to carbogen. DISCUSSION: The magnetic properties of Carbo-Rep® are promising for its future use as oxygen sensor in clinical EPR oximetry.


Subject(s)
Charcoal , Electron Spin Resonance Spectroscopy/methods , Oximetry/methods , Animals , Cell Line, Tumor , Charcoal/administration & dosage , Glioma/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Muscle, Skeletal/metabolism , Oxygen/metabolism , Particle Size , Rats , Rats, Inbred F344 , Suspensions/administration & dosage , Tumor Hypoxia
4.
J Cell Mol Med ; 23(3): 1908-1916, 2019 03.
Article in English | MEDLINE | ID: mdl-30575283

ABSTRACT

Tumour hypoxia is a well-established factor of resistance in radiation therapy (RT). Myo-inositol trispyrophosphate (ITPP) is an allosteric effector that reduces the oxygen-binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. We investigated herein the oxygenation effect of ITPP in six tumour models and its radiosensitizing effect in two of these models. The evolution of tumour pO2 upon ITPP administration was monitored on six models using 1.2 GHz Electron Paramagnetic Resonance (EPR) oximetry. The effect of ITPP on tumour perfusion was assessed by Hoechst staining and the oxygen consumption rate (OCR) in vitro was measured using 9.5 GHz EPR. The therapeutic effect of ITPP with and without RT was evaluated on rhabdomyosarcoma and 9L-glioma rat models. ITPP enhanced tumour oxygenation in six models. The administration of 2 g/kg ITPP once daily for 2 days led to a tumour reoxygenation for at least 4 days. ITPP reduced the OCR in six cell lines but had no effect on tumour perfusion when tested on 9L-gliomas. ITPP plus RT did not improve the outcome in rhabdomyosarcomas. In 9L-gliomas, some of tumours receiving the combined treatment were cured while other tumours did not benefit from the treatment. ITPP increased oxygenation in six tumour models. A decrease in OCR could contribute to the decrease in tumour hypoxia. The association of RT with ITPP was beneficial for a few 9L-gliomas but was absent in the rhabdomyosarcomas.


Subject(s)
Inositol Phosphates/pharmacology , Oxygen/metabolism , Animals , Cell Line, Tumor , Disease Models, Animal , Erythrocytes/drug effects , Erythrocytes/metabolism , Glioma/drug therapy , Glioma/metabolism , Hemoglobins/metabolism , Humans , Hypoxia/drug therapy , Hypoxia/metabolism , Mice , Mice, Inbred C3H , Mice, Nude , Oximetry/methods , Oxygen Consumption/drug effects , Rats , Rats, Inbred F344 , Rodentia
5.
Int J Radiat Oncol Biol Phys ; 96(1): 149-60, 2016 09 01.
Article in English | MEDLINE | ID: mdl-27511852

ABSTRACT

PURPOSE: In an effort to develop noninvasive in vivo methods for mapping tumor oxygenation, magnetic resonance (MR)-derived parameters are being considered, including global R1, water R1, lipids R1, and R2*. R1 is sensitive to dissolved molecular oxygen, whereas R2* is sensitive to blood oxygenation, detecting changes in dHb. This work compares global R1, water R1, lipids R1, and R2* with pO2 assessed by electron paramagnetic resonance (EPR) oximetry, as potential markers of the outcome of radiation therapy (RT). METHODS AND MATERIALS: R1, R2*, and EPR were performed on rhabdomyosarcoma and 9L-glioma tumor models, under air and carbogen breathing conditions (95% O2, 5% CO2). Because the models demonstrated different radiosensitivity properties toward carbogen, a growth delay (GD) assay was performed on the rhabdomyosarcoma model and a tumor control dose 50% (TCD50) was performed on the 9L-glioma model. RESULTS: Magnetic resonance imaging oxygen-sensitive parameters detected the positive changes in oxygenation induced by carbogen within tumors. No consistent correlation was seen throughout the study between MR parameters and pO2. Global and lipids R1 were found to be correlated to pO2 in the rhabdomyosarcoma model, whereas R2* was found to be inversely correlated to pO2 in the 9L-glioma model (P=.05 and .03). Carbogen increased the TCD50 of 9L-glioma but did not increase the GD of rhabdomyosarcoma. Only R2* was predictive (P<.05) for the curability of 9L-glioma at 40 Gy, a dose that showed a difference in response to RT between carbogen and air-breathing groups. (18)F-FAZA positron emission tomography imaging has been shown to be a predictive marker under the same conditions. CONCLUSION: This work illustrates the sensitivity of oxygen-sensitive R1 and R2* parameters to changes in tumor oxygenation. However, R1 parameters showed limitations in terms of predicting the outcome of RT in the tumor models studied, whereas R2* was found to be correlated with the outcome in the responsive model.


Subject(s)
Magnetic Resonance Imaging/methods , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/radiotherapy , Oxygen/metabolism , Tumor Hypoxia , Administration, Inhalation , Animals , Biomarkers, Tumor/metabolism , Carbon Dioxide , Cell Line, Tumor , Male , Molecular Imaging/methods , Neoplasms, Experimental/diagnosis , Prognosis , Rats , Rats, Inbred F344 , Reproducibility of Results , Sensitivity and Specificity , Treatment Outcome
6.
Contrast Media Mol Imaging ; 11(2): 115-21, 2016.
Article in English | MEDLINE | ID: mdl-27041693

ABSTRACT

Early markers of treatment response may help in the management of patients by predicting the outcome of a specific therapeutic intervention. Here, we studied the potential value of diffusion-weighted MRI (DW-MRI) and (18)F-fluorothymidine ((18)F-FLT), markers of cell death and cell proliferation respectively, to predict the response to irradiation. In addition, dose escalation and/or carbogen breathing were used to modulate the response to irradiation. The studies were performed on two hypoxic rat tumor models: rhabdomyosarcoma and 9L-glioma. The rats were imaged using MRI and PET before and two days after the treatment. In both tumor models, changes in ADC (apparent diffusion coefficient) and (18)F-FLT SUV (standardized uptake value) were significantly correlated with the tumor growth delay. For both tumor models, the ADC values increased in all irradiated groups two days after the treatment while they decreased in the untreated groups. At the same time, the uptake of (18)F-FLT increased in the untreated groups and decreased in all treated groups. Yet, ADC values were not sensitive enough to predict the added value of dose escalation or carbogen breathing in either model. Change in (18)F-FLT uptake was able to predict the higher tumor response when using increased dose of irradiation, but not when using a carbogen breathing challenge. Our results also emphasize that the magnitude of change in (18)F-FLT uptake was strongly dependent on the tumor model.


Subject(s)
Diffusion Magnetic Resonance Imaging/methods , Glioma/diagnostic imaging , Neoplasms, Experimental/diagnostic imaging , Positron-Emission Tomography/methods , Rhabdomyosarcoma/diagnostic imaging , Animals , Cell Hypoxia/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Fluorodeoxyglucose F18/administration & dosage , Fluorodeoxyglucose F18/chemistry , Glioma/pathology , Glioma/radiotherapy , Humans , Neoplasms, Experimental/pathology , Neoplasms, Experimental/radiotherapy , Rats , Rhabdomyosarcoma/pathology , Rhabdomyosarcoma/radiotherapy
7.
Radiother Oncol ; 114(2): 189-94, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25616539

ABSTRACT

PURPOSE: To assess the predictive value of hypoxia imaging by (18)F-FAZA PET in identifying tumors that may benefit from radiotherapy combined with nimorazole, a hypoxic radiosensitizer. MATERIAL AND METHODS: Rats of two tumor models (Rhabdomyosarcoma and 9L-glioma) were divided into two treated groups: radiotherapy (RT) alone or RT plus nimorazole. (18)F-FAZA PET images were obtained to evaluate tumor hypoxia before the treatment. Treatment outcome was assessed through the tumor growth time assay, defined as the time required for tumor to grow to 1.5 times its size before irradiation. RESULTS: For rhabdomyosarcomas, the benefit of adding nimorazole to RT was not significant when considering all tumors. When stratifying into more and less hypoxic tumors according to the median (18)F-FAZA T/B ratio, we found that the combined treatment significantly improved the response of the "more hypoxic" subgroup, while there was no significant difference in the tumor growth time between the two treatment modalities for the "less hypoxic" subgroup. For 9L-gliomas, a clear benefit was demonstrated for the group receiving RT+nimorazole. However, the individual responses within the RT+nimorazole group were highly variable and independent of the (18)F-FAZA uptake. CONCLUSIONS: (18)F-FAZA PET may be useful to guide hypoxia-directed RT using nimorazole as radiosensitizer. It identified a subgroup of more hypoxic tumors (displaying T/B ratio>2.72) that would benefit from this combined treatment. Nevertheless, the predictive power was limited to rhabdomyosarcomas and ineffective for 9L-gliomas.


Subject(s)
Glioma/diagnostic imaging , Glioma/therapy , Nimorazole/pharmacology , Nitroimidazoles , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/therapy , Animals , Cell Hypoxia/physiology , Chemoradiotherapy , Disease Models, Animal , Fluorine Radioisotopes , Glioma/drug therapy , Glioma/radiotherapy , Male , Positron-Emission Tomography/methods , Radiopharmaceuticals , Random Allocation , Rats , Rats, Inbred F344 , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/radiotherapy
8.
Radiother Oncol ; 113(2): 204-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25434767

ABSTRACT

BACKGROUND AND PURPOSE: Hypoxia-driven intervention (oxygen manipulation or dose escalation) could overcome radiation resistance linked to tumor hypoxia. Here, we evaluated the value of hypoxia imaging using (18)F-FAZA PET to predict the outcome and guide hypoxia-driven interventions. MATERIAL AND METHODS: Two hypoxic rat tumor models were used: rhabdomyosarcoma and 9L-glioma. For the irradiated groups, the animals were divided into two subgroups: breathing either room air or carbogen. (18)F-FAZA PET images were obtained just before the irradiation to monitor the hypoxic level of each tumor. Absolute pO2 were also measured using EPR oximetry. Dose escalation was used in Rhabdomyosarcomas. RESULTS: For 9L-gliomas, a significant correlation between (18)F-FAZA T/B ratio and tumor growth delay was found; additionally, carbogen breathing dramatically improved the tumor response to irradiation. On the contrary, Rhabdomyosarcomas were less responsive to hyperoxic challenge. For that model, an increase in growth delay was observed using dose escalation, but not when combining irradiation with carbogen. CONCLUSIONS: (18)F-FAZA uptake may be prognostic of outcome following radiotherapy and could assess the response of tumor to carbogen breathing. (18)F-FAZA PET may help to guide the hypoxia-driven intervention with irradiation: carbogen breathing in responsive tumors or dose escalation in tumors non-responsive to carbogen.


Subject(s)
Carbon Dioxide/administration & dosage , Cell Hypoxia/drug effects , Glioma/diagnostic imaging , Nitroimidazoles , Oxygen/administration & dosage , Radiotherapy Planning, Computer-Assisted/methods , Rhabdomyosarcoma/diagnostic imaging , Animals , Cell Hypoxia/physiology , Diagnostic Imaging , Disease Models, Animal , Glioma/metabolism , Glioma/radiotherapy , Male , Oximetry , Oxygen/metabolism , Partial Pressure , Positron-Emission Tomography/methods , Prognosis , Random Allocation , Rats , Rats, Inbred F344 , Rhabdomyosarcoma/metabolism , Rhabdomyosarcoma/radiotherapy
9.
Radiother Oncol ; 105(1): 29-35, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22677038

ABSTRACT

BACKGROUND AND PURPOSE: (18)F-FAZA is a nitroimidazole PET tracer that can provide images of tumor hypoxia. However, it cannot provide absolute pO(2) values. To qualify (18)F-FAZA PET, we compared PET images to pO(2) measured by OxyLite, EPR oximetry and (19)F-MRI. MATERIALS AND METHODS: Male WAG/Rij rats grafted with rhabdomyosarcoma were used. Tumor oxygenation was modified by gas breathing (air or carbogen). The same day of PET acquisition, the pO(2) was measured in the same tumor either by OxyLite probes (measurement at 10 different sites), EPR oximetry using low frequency EPR or (19)F-relaxometry using 15C5 on an 11.7T MR system. RESULTS: There was a good correlation between the results obtained by PET and EPR (R = 0.93). In the case of OxyLite, although a weaker correlation was observed (R = 0.55), the trend for two values to agree was still related to the inverse function theoretically predicted. For the comparison of (18)F-FAZA PET and (19)F-MRI, no change in T(1) was observed. CONCLUSIONS: A clear correlation between (18)F-FAZA PET image intensities and tumor oxygenation was demonstrated, suggesting that (18)F-FAZA PET is a promising imaging technique to guide cancer therapy.


Subject(s)
Magnetic Resonance Imaging/methods , Nitroimidazoles , Oximetry/methods , Positron-Emission Tomography/methods , Animals , Cell Hypoxia , Fluorine Radioisotopes , Male , Neoplasms, Experimental/diagnostic imaging , Radiopharmaceuticals , Rats , Rhabdomyosarcoma/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...